Acadian Asset Management
AVIR icon

Acadian Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Acadian Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.46M Buy
2,035,192
+452,375
+29% +$2.25M 0.01% 606
2026
Q1 		$8.51M Buy
1,582,817
+278,913
+21% +$1.28M 0.01% 570
2025
Q4 		$4.65M Buy
1,303,904
+334,131
+34% +$1.06M 0.01% 672
2025
Q3 		$2.81M Buy
969,773
+51,927
+6% +$177K ﹤0.01% 802
2025
Q2 		$3.3M Hold
917,846
– – 0.01% 692
2025
Q1 		$2.74M Sell
917,846
-15,079
-2% -$47.1K 0.01% 678
2024
Q4 		$3.12M Hold
932,925
– – 0.01% 657
2024
Q3 		$3.12M Sell
932,925
-1,580
-0.2% -$5.73K 0.01% 620
2024
Q2 		$3.09M Sell
934,505
-27,953
-3% -$104K 0.01% 639
2024
Q1 		$3.89M Hold
962,458
– – 0.01% 530
2023
Q4 		$2.93M Sell
962,458
-25,458
-3% -$77.1K 0.01% 581
2023
Q3 		$2.96M Sell
987,916
-8,359
-0.8% -$28.4K 0.01% 578
2023
Q2 		$3.72M Sell
996,275
-114,440
-10% -$428K 0.02% 529
2023
Q1 		$3.72M Buy
1,110,715
+242,465
+28% +$984K 0.02% 536
2022
Q4 		$4.17M Buy
868,250
+42,487
+5% +$215K 0.02% 495
2022
Q3 		$4.7M Buy
825,763
+111,341
+16% +$852K 0.03% 410
2022
Q2 		$5.07M Sell
714,422
-138,154
-16% -$943K 0.03% 411
2022
Q1 		$6.15M Buy
852,576
+580,315
+213% +$3.94M 0.03% 420
2021
Q4 		$2.43M Buy
272,261
+241,916
+797% +$3.77M 0.01% 610
2021
Q3 		$1.06M Sell
30,345
-3,369
-10% -$93.4K ﹤0.01% 833
2021
Q2 		$724K Buy
+33,714
New +$1.01M ﹤0.01% 1026

Other funds holding AVIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Acadian Asset Management's AVIR Position: Q2 2026 in Review

Acadian Asset Management increased its Atea Pharmaceuticals (AVIR) stake by 29% in Q2 2026, buying an estimated $2.25M and bringing the position to 2,035,192 shares worth $9.46M. The position accounts for 0.01% of the portfolio, ranked #606.

Acadian Asset Management first reported a position in AVIR in Q2 2021 and has held it in 21 quarters since. 116 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Acadian Asset Management held 2,035,192 shares of Atea Pharmaceuticals worth $9.46M as of Q2 2026.
  • Acadian Asset Management bought 452,375 Atea Pharmaceuticals shares in Q2 2026, an estimated $2.25M.
  • Atea Pharmaceuticals made up 0.01% of Acadian Asset Management's portfolio in Q2 2026, its #606 holding.
  • Acadian Asset Management first reported a position in Atea Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • 116 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.